NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."

85mg/m2 intravenously on day 1

150mg/m2 intravenously on day 1

50mg as an intravenous bolus

2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1

6mg by subcutaneous injection to be given on day 3 of each cycle.